RR is 48 year old male recently diagnosed with Type II Diabetes. He is 80 kg and his serum creatinine is 0.8 mg/dL. Which is the recommended first line, non-insulin hypoglycemic therapy for RR per the American Diabetes Association (ADA) Guidelines?

Rationale: A. Metformin is the established first-line pharmacological treatment for Type 2 diabetes due to its high efficacy in lowering HgbA1c, low cost, and favorable safety profile. It primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues without causing weight gain or hypoglycemia. RR has a normal serum creatinine of 0.8 mg/dL, confirming adequate renal function for this biguanide. B. Pioglitazone is generally reserved as a secondary or tertiary add-on therapy rather than a first-line agent for newly diagnosed patients. While it effectively reduces insulin resistance by activating PPAR-gamma receptors, it is associated with side effects such as weight gain, edema, and a potential risk for bone fractures. ADA guidelines prioritize agents with more favorable benefit-to-risk ratios like metformin for initial monotherapy. C. Sulfonylureas like glipizide are effective at lowering blood glucose by stimulating insulin secretion from pancreatic beta cells but carry a significant risk of hypoglycemia and weight gain. Because of these adverse effects, they are no longer preferred as the initial choice when other options are available. Modern guidelines emphasize starting with medications that do not trigger hypoglycemic events, especially in newly diagnosed individuals. D. Sitagliptin is a DPP-4 inhibitor that provides a modest reduction in glucose levels with a very low risk of hypoglycemia and neutral effects on weight. While it is a well-tolerated medication, its glucose-lowering potency is generally lower than that of metformin. Consequently, it is typically utilized as an alternative for patients who cannot tolerate metformin or as an add-on in combination therapy.